Transgenic interleukin 2 secreted by CML dendritic cells stimulates autologous TH1 T cells

Cytotherapy

Volumn 3, Issue 2, 2001, Pages 97-105

  Dietz, A B ^a,b   Litzow, M R ^b   Bulur, P A ^a   Vuk Pavlovic S ^a,b  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4;

ADENOVIRUS; ARTICLE; AUTOLOGOUS MIXED LYMPHOCYTE REACTION; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; PROTEIN SECRETION; TH1 CELL; VIRUS INFECTION;

EID: 0034997855     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240152584505     Document Type: Article

References (33)

1. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1997;63:125-30.
2. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132: 1497-99.
3. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 1973;243:290-93.
4. Bartram CR, de Klein A, Hagemeijer A et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-80.
5. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-54.
6. Yotnda P, Firat H, Garcia-Pons F et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998;101:2290-96.
7. + T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997;90:290-97.
8. MacIntyre AR, Christmas SE, Clark RE. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide. Exp Hematol 1996;24:1307-11.
9. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
10. Mehta J. Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leukemia Lymphoma 1993;10:427-37.
11. Eibl B, Ebner S, Duba C et al. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 1997;20:215-23.
12. Choudhury A, Gajewski JL, Liang JC et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997;89:1133-12.
13. Smit WM, Rijnbeek M, van Bergen CAM et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Human Immunol 1997;53:216-23.
14. Fujii S, Shimizu K, Fujimoto K et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res 1999;90:1117-29.
15. Cervantes F, Pierson BA, McGlave PB et al. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996;87:2476-85.
16. - blood leukocyte cultures as determined by reverse transcriptase-polymerase chain reaction. Exp Hematol 1998;26:1265-70.
17. + cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998;92:3318-27.
18. Varadi G, Ackerstein A, Ben-Neriah S, Nagler A. Adoptive cell-mediated immunotherapy with interlukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient. Bone Marrow Transplant 1998;21: 93-96.
19. Lonnqvist B, Brune M, Ljungman P. Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML - a case report. Bone Marrow Transplant 1996;18:241-12.
20. Goodman M, Spector N, Rodrigues G, Cassileth PA. Interleukin-2 therapy for advanced chronic myeloid leukemia. Leukemia 1998;12:1682-84.
21. Pierson BA, Miller JS. The role of autologous natural killer cells in chronic myelogenous leukemia. Leukemia Lymphoma 1997;27:387-99.
22. Dietz AB, Vuk-Pavlović S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998;91:392-98.
23. Dietz AB, Bulur PA, Erickson MR et al. Optimizing preparation of normal dendritic cells and bcr-abl positive mature dendritic cells derived from immunomagnetically purified CD14 positive cells. J Hematotherapy Stem Cell Res 2000;9: 95-101.
24. Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-42.
25. Hilkens CM, Kalinski P, de Boer B, Kapsenberg M. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997;90:1920-26.
26. Heufler C, Kalinski P, de Boer B, Kapsenberg M. Interleukin-12 is produced by dendritic cell and mediates T helper 1 development as well as interferon-γ production by T cells. Eur J Immunol 1996;26:659-68.
27. Labeur MS, Roters B, Pers B et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999;162:168-75.
28. Addison CL, Bramson JL, Hitt MM et al. Intratumoral coinjection of adenovirual vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy 1998;5:1400-09.
29. Shimizu K, Fields RC, Giedlin M, Mule JJ. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 1999;96:2268-73.
30. Brossart P, Goldrath AW, Butz EA et al. Virus-mediated delivery of antigenic epitopes in dendritic cells as a means to induce CTL. J Immunol 1997;158:3270-76.
31. Molnar-Kimber KL, Sterman DH, Chang M et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Human Gene Therapy 1998;9:2121-33.
32. Ranieri E, Herr W, Gambotto A et al. Dendritic cells transfected with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: A new modality for vaccination. J Virol 1999;73:10416-25.
33. Morse MA, Coleman RE, Akabani G et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56-68.